Metagenomi Therapeutics, Inc. (MGX)

NMS – Real vaqt narxi. Valyuta: USD

1.25

+0.06 (5.04%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

1.25

0.00 (0.00%)

Bozordan keyin: Jun 26, 2026, 4:10 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Metagenomi Therapeutics, Inc. (MGX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Metagenomi Therapeutics, Inc. (MGX)

Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference

Metagenomi Therapeutics (MGX) Reports Q1 Loss, Misses Revenue Estimates

Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency

Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Metagenomi Therapeutics (MGX) Reports Q4 Loss, Misses Revenue Estimates

Videolar

No Data

Press-relizlar

Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency

Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Search stocks

Metagenomi Therapeutics, Inc. (MGX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Metagenomi Therapeutics, Inc. (MGX)

Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference

Metagenomi Therapeutics (MGX) Reports Q1 Loss, Misses Revenue Estimates

Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency

Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Metagenomi Therapeutics (MGX) Reports Q4 Loss, Misses Revenue Estimates

Videolar

No Data

Press-relizlar

Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency

Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?